Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
15 Août 2024 - 6:18PM
Edgar (US Regulatory)
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
|
|
|
|
|
|
|
|
FORM 12b-25 |
SEC FILE NUMBER
333-194337 |
|
NOTIFICATION OF LATE FILING |
CUSIP NUMBER
|
(Check one): |
o Form 10-K |
o Form 20-F |
o Form 11-K |
|
|
x Form 10-Q |
o Form 10-D |
o Form N-CEN |
o Form N-CSR |
|
For Period Ended: June
30,
2024 |
|
o Transition Report on Form 10-K |
|
o Transition Report on Form 20-F |
|
o Transition Report on Form 11-K |
|
o Transition Report on Form 10-Q |
|
o For the Transition Period Ended: |
|
Read Instructions (on back page) Before Preparing Form. Please Print or Type. |
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: |
|
|
PART I — REGISTRANT INFORMATION |
|
MediXall Group,
Inc. |
Full Name of Registrant |
|
|
Former Name if Applicable |
|
104 N 4TH ST. |
Address of Principal Executive Office (Street
and Number) |
|
LEESBURG,
FL 34748 |
City, State and Zip Code |
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
x |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail why Forms
10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
Certain financial and other information necessary for
an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort
or expense.
PART IV — OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification.
Travis
Jackson |
|
877 |
|
558-7750 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s). Yes o No x
(3) Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion thereof? Yes o No x
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
|
|
|
|
|
|
|
|
|
MediXall Group, Inc. |
|
(Name of Registrant as Specified in Charter) |
|
|
|
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. |
|
|
Date: |
August 15, 2024 |
|
|
By: |
/s/ Travis Jackson |
|
|
|
|
|
Travis Jackson, Chief Financial Officer |
|
|
|
|
|
|
|
MediXall (CE) (USOTC:MDXL)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
MediXall (CE) (USOTC:MDXL)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
Real-Time news about MediXall Group Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur MediXall Group Inc (CE)